Research
Hormonal
Omega-3 fatty acid supplementation (≥1 g/day) supports muscle quality, cardiovascular health, and reduces inflammation during GLP-1RA treatment.
Take at least 1 gram of Omega-3 fatty acids daily. This helps protect your heart, reduces inflammation, and may support muscle quality while you lose weight.
GoodSupportsHIGH confidence
Fish oil supplementation has been shown to be correlated with reduced cardiovascular disease risk... emerging research with fish oil supplementation finds positive impacts on muscle quality.
Why this rating
Strong evidence for cardiovascular and muscle quality benefits in general populations.
Source
Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review
Brittany V.B. Johnson et al. · Obesity Pillars · 2025
DOI 10.1016/j.obpill.2025.100209
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Whey protein supplementation (20-40 g/day) combined with resistance training preserves lean body mass and improves strength during GLP-1RA-induced weight loss.Good
- Multivitamin supplementation is recommended for individuals using GLP-1 receptor agonists to address micronutrient insufficiencies resulting from reduced caloric intake and gastrointestinal side effects.Moderate
- HMB (3 g/day) and Creatine (5 g/day) supplementation, combined with resistance training, helps preserve lean body mass and strength during GLP-1RA-induced weight loss.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →